Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, an Open Clinical Trials to Evaluate Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine in Healthy Adults

NCT03572491 is registered in ClinicalTrials.gov with Research Institute for Biological Safety Problems as lead sponsor.

NCT NCT03572491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03572491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, an Open Clinical Trials to Evaluate Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine in Healthy Adults
Lead sponsor
Research Institute for Biological Safety Problems
Phase
Phase 3
Overall status
Completed
Start date
September 18, 2017
Completion date
May 21, 2018
Enrollment
2,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human influenza